Ohio University

skip to main content

OHIO Expert

Photo of John Kopchick

John Kopchick, Ph.D.

Areas of Expertise:
Acromegaly, Aging, Autoimmune Diseases, Cancer, Diabetes, Growth Hormone, Human Growth Hormone (HGH), Insulin, SOMAVERT

High Res Photo

Dr. Kopchick is an expert on growth hormone (GH). With over 20 years of research experience on human and animal GH, Kopchick and colleagues have focused on the molecular biology of GH in relation to growth, obesity, insulin resistance, diabetes and aging.

Kopchick's work is also commercially successful. In 1987, he and a graduate student discovered an hGH receptor antagonist, which blocks the normal action of the hormone. After 15 years of continuous research, development and clinical trials, the U.S. Food and Drug Administration approved the compound that Kopchick discovered as a drug.

The major pharmaceutical company, Pfizer, then purchased the hGH receptor antagonist technology and has commercially marketed it under the name SOMAVERT (Pegvisomant for injection). The drug is used as a treatment for acromegaly, a growth disorder marked by excessive levels of hGH that results in enlargement of the hands and feet, facial disfiguration and multiple organ disorders. If left untreated, premature death can ensue. About 40,000 individuals are diagnosed with acromegaly worldwide.

In the years since Pfizer's commercial launch of SOMAVERT, Ohio University has received more than $75 million in royalty income from the license.

Additionally, in 2007, Kopchick, along with colleague Dr. Jens Otto Jorgensen, received a $482,000 grant from the World Anti-Doping Agency to find a marker that would make testing for hGH as a performance-enhancing drug possible. The hormone is alleged to be one of the more common performance-enhancing drugs used by athletes as it is virtually undetectable. Currently, there is no convenient blood or urine biomarker test that will detect hGH doping.

Kopchick and his colleagues are conducting studies to find biomarkers that will make testing more accurate, sensitive and reliable. This research hopefully will result in the ability to determine just how many professional athletes are using hGH as a performance-enhancing drug.

Kopchick is also lead investigator for the university's Edison Biotechnology Institute, an interdisciplinary team of scientists working on new ways to diagnose and treat growth disorders, diabetes, obesity, auto-immune diseases, inflammation, aging, infectious diseases and cancer.

Dr. Kopchick participates in  the Ohio University Collaborative on Aging, which brings together researchers, educators, service providers and students with aging-related interests. The University-wide interdisciplinary network focuses on improving the lives of older adults and optimizing quality of life across the lifespan, especially in underserved populations. 

Kopchick's Media Placements include:

  • New York Times
  • Fox Business Network
  • ABC 6 / Fox 28 TV, Columbus
  • Times Union (NY)
  • News Times (CT)
  • New Scientist
  • Science Daily (MD)
  • Times-News (NC)
  • The Ledger (FL)
  • Herald Journal (SC)
  • Sarasota Herald Tribune
  • Lexington Dispatch (NC)
  • Gainesville Sun
  • Pittsburgh Post-Gazette
  • Medical News Today
  • Greenwich Times (CT)
  • Columbus Dispatch
  • Beaumont Enterprises
  • The Athens News
  • The Athens Messenger
  • Primetime Newspapers
  • dLife CNBC online
  • WOUB-TV (OH)

Expert Video

Growth Hormones & Disorders

Media Contacts

E-Mail monitored by University Communications and Marketing Team
media@ohio.edu
After hours on-call media specialist: 740.593.2200

Social OHIO

OHIO in the News

view more